Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 5/20 | 0.38 |
| ▸ | PDE2A | O00408 | 3/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.36 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24973993 | 1.00 | TRPV4 (0.43) | TRPV4TRPV3PDE2AP2RX7GPR139 | |
| SCHEMBL10115935 | 0.83 | TRPV4 (0.46) | TRPV4TRPV3PDE2AP2RX7GPR139 | |
| SCHEMBL14612275 | 0.83 | TRPV4 (0.46) | TRPV4TRPV3PDE2AP2RX7GPR139 | |
| SCHEMBL469196 | 0.83 | TRPV4 (0.46) | TRPV4TRPV3PDE2AP2RX7GPR139 | |
| SCHEMBL21346253 | 0.82 | TRPV4 (0.48) | TRPV4TRPV3PDE2AP2RX7GPR139 | |
| SCHEMBL13745241 | 0.82 | TRPV4 (0.48) | TRPV4TRPV3PDE2AP2RX7GPR139 | |
| SCHEMBL19773439 | 0.82 | TRPV4 (0.48) | TRPV4TRPV3PDE2AP2RX7GPR139 | |
| SCHEMBL21346243 | 0.81 | TRPV3 (0.40) | TRPV4TRPV3PDE2AP2RX7GPR139 | |
| SCHEMBL14313737 | 0.81 | TRPV4 (0.47) | TRPV4TRPV3PDE2AP2RX7 | |
| SCHEMBL2609310 | 0.78 | TRPV4 (0.52) | TRPV4TRPV3PDE2AP2RX7GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | TRPV4 4185/4885TRPV3 3644/4885PDE2A 682/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | TRPV4 4185/4885TRPV3 3644/4885PDE2A 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.